GLPwatch
Papers (10373)
Page 42 of 173, ranked by citation count.
- Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.
- Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes.
- Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.
- Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
- Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations.
- Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients.
- Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
- Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.
- Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.
- Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice.
- Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
- Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.
- Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.
- Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future.
- The effects of liraglutide on male fertility: a case report.
- The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
- Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.
- Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
- Cagrilintide plus semaglutide for obesity management.
- Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
- A wearable osmotic microneedle patch provides high-capacity sustained drug delivery in animal models.
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
- Is Exenatide a Treatment for Parkinson's Disease?
- Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review.
- Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
- Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
- Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.
- Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
- A red light-controlled probiotic bio-system for in-situ gut-brain axis regulation.
- Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.
- Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes.
- Interspecies modeling and prediction of human exenatide pharmacokinetics.
- Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting.
- Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects.
- Effects of GLP-1 receptor agonists on neurological complications of diabetes.
- Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
- Clinical Effectiveness of Intravenous Exenatide Infusion in Perioperative Glycemic Control after Coronary Artery Bypass Graft Surgery: A Phase II/III Randomized Trial.
- Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
- Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes.
- Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
- Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI).
- Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.
- The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
- The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4.
- Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
- Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
- Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia.
- Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats.
- Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs.
- Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
- The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca(2+) signalling in steatotic hepatocytes.
- Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in Suncus murinus (house musk shrew).
- Multilayer nanoparticles for sustained delivery of exenatide to treat type 2 diabetes mellitus.
- Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status.
- Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice.
- Evaluation of the in vitro and in vivo angiogenic effects of exendin-4.
- Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes.
- Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
- Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
- Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice.